



excelra

GOBIOM Use Case 2



Identification of efficacy, response to therapy and drug resistance biomarkers in breast cancer



- ✓ A drug development team in a big pharmaceutical company working on BCL-2 inhibitors is keen on identifying biomarkers of efficacy, response to therapy and drug resistance in breast cancer
- ✓ Once the efficacy biomarkers have been identified the group intends to design effective clinical trials to study the effectiveness of the drug
- ✓ Also, identification of response to therapy and resistance biomarkers will aid in identifying right study population for clinical trials

- ✓ A search in GOBIOM database by keyword 'BCL-2' in 'Target Name', keyword "Efficacy" in 'Application' and 'Breast cancer' in 'Indication' retrieves all the efficacy biomarkers reported in breast cancer

Home / Search / Advanced Search

Selected Fields
 Breast Cancer ✕ Efficacy ✕ Apoptosis regulator Bcl-2 ✕

Search Type
 Contains Starts With

Biomarker Clinical Status
 Clinical Exploratory Clinical Pre-Clinical Safety / Toxicity

Biomarker

Biomarker Name Biomarker Name	Biomarker Nature Biomarker Nature	Biomarker Type Biomarker Type	Application Application	Biomarker Qualification Biomarker Qualification
----------------------------------	--------------------------------------	----------------------------------	----------------------------	--

Disease

Therapeutic Area Therapeutic Area	Disease Name Disease Name	Disease Sub-type Disease Sub-type	Disease Stage Disease Stage	Disease Grade Disease Grade
--------------------------------------	------------------------------	--------------------------------------	--------------------------------	--------------------------------

Clinical

Clinical Trial ID Clinical Trial ID	Sponsor / Collaborator Sponsor / Collaborator	Phase Phase	Completion Status Completion Status	Ethnicity Ethnicity
--	--	----------------	--	------------------------


Drug

Drug Name Drug Name	Drug Target Drug Target	Adverse Event Adverse Event	Organ Disorder Organ Disorder	Organ Disorder Sub-type Organ Disorder Sub-type
------------------------	----------------------------	--------------------------------	----------------------------------	--

Hide Filters

Applied Filters [Collapse All](#)

- Biomarker +
- Indication +
- Application +
- Drugs +
- Phenotypes +
- Clinical Trials +
- Pathways +
- Gene Ontology +
- Year of Publication +



Selected Fields: diseasename : Breast Cancer, Application : Efficacy, drugtarget : Apoptosis regulator Bcl-2
Attributes Fields:

Show/Hide attributes

Save Query

Number of Records : 273

10 Show entries

Search:



Previous 1 2 3 4 5 ... 28 Next

Watch	Visualization	EBMID	Biomarker Name	Disease Name	Biomarker Type	Biomarker Class	Biomarker Status	Approval Status	Applications	Drugs	No of Clinical Trials	No of References
<input type="checkbox"/>		ONC-34937	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Drug Resistance, Response To Therapy, (more...)	BIBW 2992, VORINOSTAT, PEGFILGRASTIM, (more...)	63	380
<input type="checkbox"/>		ONC-15931	ESTROGEN RECEPTOR	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Drug Resistance, Response To Therapy, (more...)	ADRIAMYCIN, CYTOXAN, FLUVASTATIN SODIU(more...)	51	155
<input type="checkbox"/>		ONC-37936	PROGESTERONE RECEPTOR	Breast Cancer	Proteomic	Disease	Clinical	Biomarker/Assay	Prognosis, Diagnosis, Response To Ther(more...)	MIFEPRISTONE, GEMCITABINE, FULVESTRANT(more...)	31	116

Identification of qualified and most relevant efficacy biomarkers would aid the group in

- ✓ Designing effective clinical trials
- ✓ Reduce biomarker discovery costs
- ✓ Make informed decisions i.e. crucial Go/no go decisions in drug development
- ✓ Designing later-phase clinical studies

A similar search in GOBIOM database by keyword 'BCL-2' in 'Target Name', keywords "Response to therapy" "Drug resistance" in 'Application' and 'Breast cancer' in 'Indication' retrieves all the drug response biomarkers reported in breast cancer

Home / Search / Advanced Search

Selected Fields
 Drug Resistance x Response To Therapy x Breast Cancer x Apoptosis regulator Bcl-2 x

Search Type
 Contains Starts With

Biomarker Clinical Status
 Clinical Exploratory Clinical Pre-Clinical Safety / Toxicity

Biomarker
 Biomarker Name: Biomarker Nature: Biomarker Type: Application: Biomarker Qualification:
 Biomarker Pathways:


Disease
 Therapeutic Area: Disease Name: Disease Sub-type: Disease Stage: Disease Grade:

Clinical
 Clinical Trial ID: Sponsor / Collaborator: Phase: Completion Status: Ethnicity:

Drug
 Drug Name: Drug Target: Adverse Event: Organ Disorder: Organ Disorder Sub-type:

Home / Search / Advanced Search Result

Selected Fields: Drug Resistance, Response To Therapy, Breast Cancer, Apoptosis regulator Bcl-2
 Attributes Fields:




Number of Records: 143
 Show entries: 10

#	Watch	Visualization	EBMID	Biomarker Name	Disease Name	Biomarker Type	Biomarker Class	Biomarker Status	Approval Status	No of Applications	No of Drugs	No of Clinical Trials	No of References
1			CNC-3858	RESPONSE EVALUATION CRITERIA IN SOLID (more...)	Breast Cancer	Scoring scale	Disease	Critical		3	200	475	558
2			CNC-4307	EORTC QUALITY OF LIFE QUESTIONNAIRE (E(q...))	Breast Cancer	Scoring scale	Disease	Critical		4	51	95	103
3			CNC-3425	EPIDERMAL GROWTH FACTOR RECEPTOR	Breast Cancer	Proteomic	Disease	Critical		6	35	16	92
4			CNC-4458	VASCULAR ENDOTHELIAL GROWTH FACTOR	Breast Cancer	Proteomic	Disease	Critical		5	45	19	89
5			CNC-3526	PIK3CA MUTATION	Breast Cancer	Genomic	Disease	Critical		6	41	26	71

Identification of qualified and most relevant drug response biomarkers would aid the group in

- ✓ Stratification of patients who are most likely to respond to treatment
- ✓ Designing tailor made treatment regimens based on their predicted response
- ✓ Segregating patients with resistance phenotypes into focused treatment groups



www.excelra.com

THANK YOU



Disclaimer: This communication is for the intended recipient. The whole or part of this communication should not be transmitted to any external entity or enterprise without the consent of Excelra Knowledge Solutions. If you have received this by mistake or you are not the intended recipient, kindly delete it and immediately inform us.

